|
Astrocytic
Tumorss
|
|
|
|
Michael
L. Gruber, Deborah B Gruber
Phase
II Treatment of Recurrent Malignant Astrocytoma with Temozolomide and
Irinotecan
ASCO Proceedings, 2001
Annual Meeting, Abstract No. 2043
|
|
|
Sathornsumetee S, Cao Y, Marcello JE, Herndon JE
2nd, McLendon RE, Desjardins A, Friedman HS, Dewhirst MW, Vredenburgh JJ,
Rich JN
Tumor angiogenic and hypoxic profiles predict radiographic response and
survival in malignant astrocytoma patients treated with bevacizumab and
irinotecan
J
Clin Oncol. 2008 Jan 10;26(2):271-8
 Abstract |
DBLinks | BL 7:6
|
|
|
Glioblastoma
|
|
|
|
A. A. Brandes, A. Tosoni, M.
Reni, F. Valduga, U. Basso, S. Lonardi, L. M. Pasetto, V. Blatt, S.
Monfardini, M. Ermani
Second line BCNU plus CPT-11
chemotherapy in recurrent glioblastoma (GBM): Phase II study of GICNO
(Italian Neuro-Oncology Group)
40th
ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1516
|
|
|
Chamberlain MC
Bevacizumab Plus Irinotecan in Recurrent Glioblastoma
J Clin Oncol. 2008 Feb 20;26(6):1012-1013
Abstract |
 Full Text |
 Reprint |
DBLinks | BL 7:5
|
|
Chamberlain
MC
Salvage
chemotherapy with CPT-11 for recurrent glioblastoma multiforme
J Neurooncol 2002 Jan;56(2):183-8
|
|
|
Chowdhary S, Wong ET
Bevacizumab combined with irinotecan for recurrent glioblastoma
multiforme-improvement over available therapy?
Nat Clin Pract Neurol. 2008 Jan 22. [Epub ahead of print]
Abstract |
DBLinks | BL 7:3
|
|
K. A. Jaeckle, K. V.
Ballman, P. Schomberg, J. Uhm, B.
Schiethauer, C. Giannini, S. Felton, P.
Brown, B. C. Jan NCCTG
N997D: Pilot trial of CPT11 during RT followed by CPT11 and BCNU in newly
diagnosed glioblastoma (GBM) patients: A North Central Cancer Group (NCCTG)
study
2005
ASCO Annual Meeting. Orlando, FL. May 13-17. Abstract No. 1514.
Journal of Clinical Oncology, Vol 23, No 16S (June 1 Supplement), 2005:
1514
|
|
|
Puduvalli VK, Giglio P, Groves MD, Hess KR,
Gilbert MR, Mahankali S, Jackson EF, Levin VA, Conrad CA, Hsu SH, Colman H,
de Groot JF, Ritterhouse MG, Ictech SE, Yung WK
Phase II trial of irinotecan and thalidomide in adults with recurrent
glioblastoma multiforme
Neuro Oncol. 2008 Feb 26; [Epub ahead of print]
Abstract |
DBLinks | BL 7:6
|
|
|
James J. Vredenburgh,
Annick Desjardins, David A. Reardon, Henry
S. Friedman
In Reply
Journal of Clinical Oncology, Vol 26, No 6 (February 20),
2008: pp. 1013. DOI:
10.1200/JCO.2007.15.1746
Abstract |
Full Text |
Reprint |
DBLinks | BL 7:5
|
|
|
Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Marcello J, Reardon DA, Quinn JA, Rich
JN,
Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD,
Friedman AH, Friedman HS.
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme
J
Clin Oncol. 2007 Oct 20;25(30):4722-9.
Abstract |
Full
Text |
Reprint
|
DBLinks
|
|
Yinglin
Wang, Linda M. Liau, Timothy F. Cloughesy, Paul S. Mischel
p53 status determines the cell fate of
glioblastoma cells in response to SN-38
Proceedings of the AACR, Volume 44, 2nd ed., July 2003, Abstract No. 2683
|
|
|
Glioma (High-Grade)
|
|
|
|
W.
Adler, F. C. Lee
A
phase I trial using combination irinotecan and thalidomide for recurrent CNS
tumors
39th
ASCO Annual Meeting. Chicago, IL. May 31-June 3, 2003.
Abstract No. 489
|
|
Mary
L Affronti, David Reardon, Deborah Allen, Rodney Beason, Sridharan
Gururangan, Allan Friedman, James Herndon, Susanne Jackson, Roger McLendon,
Jennifer Quinn, Jeremy Rich, John Sampson, Amy Walker, Darell D Bigner, Henry
Friedman
A
phase II study of CPT-11 plus BCNU for adults with high grade glioma
38th
ASCO Annual Meeting. Orlando, FL. May 18-21, 2002.
Abstract No. 2091
|
|
M.
A. Badruddoja, D. Reardon, R. Beason, A. Friedman, J. A. Quinn, J.
Rich, J. Sampson, V. Stafford-Fox, D. D. Bigner, H. S. Friedman
Phase
1 study of temozolomide plus irinotecan (CPT-11) in adults with recurrent
malignant glioma
39th
ASCO Annual Meeting. Chicago, IL. May 31-June 3, 2003. Abstract No.
409
|
|
Tracy T. Batchelor, Mark R. Gilbert, Jeffrey G. Supko, Kathryn A. Carson,
Louis B. Nabors, Stuart A. Grossman, Glenn J. Lesser, Tom Mikkelsen, and Surasak
Phuphanich
Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma:
Final report of NABTT 97-11
Neuro-Oncology,
January 2004, Volume 6 Number 1, Pages 21 -- 27 (Abstract+)
|
|
J
Buckner, J Reid, L Schaaf, S Cha, K Wright, R Marks, M Wiesenfeld, A
Hatfield, J Krook, S Nair, P Schaefer, L Miller
A Phase II Trial of Irinotecan (CPT-11) in
Recurrent Glioma
ASCO Proceedings, 2000 Annual Meeting, Abstract No.
679A
|
|
Lynn G. Feun, Angela Marini,
Howard Landy, Arnold Markoe, Deborah Heros, Carlos Robles,
Cristina Herrera and Niramol Savaraj
Clinical trial of CPT-11 and VM-26/VP-16 for patients with recurrent
malignant brain tumors
J Neurooncol. 2006 Oct 19;
[Epub ahead of print]
Abstract
|
|
Friedman HS, Keir S, Pegg AE, Houghton PJ, Colvin OM, Moschel RC,
Bigner DD, Dolan ME
O6-benzylguanine-mediated
enhancement of chemotherapy
Mol Cancer Ther 2002
Sep;1(11):943-8
|
|
Allan
H Friedman, Sunil Agarwal, Brandon Evans, Amy Walker, Sandra
Tourt-Uhlig, David Reardon, Mary L Affronti, Deborah Allen, Rodney Beason,
Sridharan Gururangan, Susanne Jackson, Roger McLendon, Jennifer Quinn,
Jeremy Rich, John Sampson, Valerie Stafford-Fox, Karen Ziegler, Darell D
Bigner, Henry Friedman
Novel use of Gliadel for gliomas
38th ASCO Annual Meeting. Orlando, FL. May 18-21, 2002.
2109
|
|
Friedman
HS, Petros WP, Friedman AH, Schaaf LJ, Kerby T, Lawyer J, Parry M,
Houghton PJ, Lovell S, Rasheed K, Cloughsey T, Stewart ES, Colvin OM, Provenzale
JM, McLendon RE, Bigner DD, Cokgor I, Haglund M, Rich J, Ashley D, Malczyn J,
Elfring GL, Miller LL
Irinotecan
therapy in adults with recurrent or progressive malignant glioma
J Clin Oncol 1999
May;17(5):1516-25
|
|
M.
R. Gilbert, P. Wen, F. Lieberman, I. Robins, M. Mehta, W. K. A. Yung, S.
Chang, L. Junck, T. Cloughesy, M. Prados
Phase I/II study of
combination temozolomide (TMZ) and irinotecan (CPT-11) for recurrent
malignant gliomas: A North American Brain Tumor Consortium (NABTC) study
39th ASCO Annual Meeting.
Chicago, IL. May 31-June 3, 2003. Abstract No.
410
|
|
R. V. Larocca, A. Cervera, J.
B. Hargis, S. D. Glisson, G. H. Goldsmith, M. A. M. Laureano, B. Foreman
High-dose (HD) irinotecan in patients with
recurrent unresectable high-grade gliomas on glucoronidation-enhancing
anticonvulsants (GEACs): A phase I/II study
40th
ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1578
|
|
|
Loghin ME, Prados MD, Wen P, Junck L, Lieberman
F, Fine H, Fink KL, Metha M, Kuhn J, Lamborn K, Chang SM, Cloughesy T,
Deangelis LM, Robins IH, Aldape KD, Yung WK
Phase I Study of Temozolomide and Irinotecan for Recurrent Malignant
Gliomas in Patients Receiving Enzyme-Inducing Antiepileptic Drugs: A North
American Brain Tumor Consortium Study
Clin
Cancer Res. 2007 Dec 1;13(23):7133-8
Abstract |
DBLinks
|
|
Parker RJ, Fruehauf JP, Mehta R, Filka E, Cloughesy T
A prospective blinded study of the
predictive value of an extreme drug resistance assay in patients receiving
CPT-11 for recurrent glioma
J Neurooncol. 2004 Feb;66(3):365-75. (Abstract+)
|
|
Patel
VJ, Elion GB, Houghton PJ, Keir S, Pegg AE, Johnson SP, Dolan ME,
Bigner DD, Friedman HS
Schedule-dependent
activity of temozolomide plus CPT-11 against a human central nervous
system tumor-derived xenograft
Clin Cancer Res 2000
Oct;6(10):4154-7 (PDF Full Text)
|
|
Prados MD, Yung WK, Jaeckle KA, Robins HI, Mehta MP, Fine HA, Wen PY,
Cloughesy TF, Chang SM, Nicholas MK, Schiff D, Greenberg HS, Junck L, Fink KL,
Hess KR, Kuhn J; North American Brain Tumor Consortium study
Phase 1 trial of irinotecan (CPT-11) in patients with
recurrent malignant glioma: a North American Brain Tumor Consortium study
Neuro-oncol. 2004 Jan;6(1):44-54. (Abstract+)
|
|
Jennifer
A. Quinn, David A. Reardon, Allan H. Friedman, Jeremy N. Rich, John H.
Sampson, James Vredenburgh, Sridharan Gururangan, James M. Provenzale, Amy
Walker, Holly Schweitzer, Darell D. Bigner, Sandra Tourt-Uhlig, James E. Herndon
II, Mary Lou Affronti, Susanne Jackson, Deborah Allen, Karen Ziegler, Cindy
Bohlin, Christy Lentz, Henry S. Friedman
Phase 1 trial of irinotecan plus BCNU in
patients with progressive or recurrent malignant glioma
Neuro-Oncology, Volume 6, Number 2, Pages 145 – 153. (Abstract+)
|
|
David
A. Reardon, Jennifer A. Quinn, Jeremy N. Rich, Sridharan Gururangan, James
Vredenburgh, John H. Sampson, James M. Provenzale, Amy Walker, Michael
Badruddoja, Sandra Tourt-Uhlig, James E. Herndon II, Jeannette M. Dowell, Mary
Lou Affronti, Susanne Jackson, Deborah Allen, Karen Ziegler, Steven Silverman,
Cindy Bohlin, Allan H. Friedman, Darell D. Bigner, Henry S. Friedman
Phase 2 trial of BCNU plus irinotecan
in adults with malignant glioma
Neuro-Oncology, April 2004, Volume 6, Number 2, Pages 134 – 144. (Abstract+)
|
|
R.
Stupp, S. Ostermann, A. Calderoni, C. Uhlmann, S. Leyvraz
Temozolomide (TMZ) and
irinotecan (CPT-11) for primary brain tumors. A dose escalation study
39th ASCO Annual Meeting.
Chicago, IL. May 31-June 3, 2003. Abstract No.
415
|
|
Sandra
Tourt-Uhlig, David Reardon, Mary L Affronti, Deborah Allen, Rodney
Beason, Brandon Evans, Sridharan Gururangan, Allan Friedman, Susanne
Jackson, Roger McLendon, Jennifer Quinn, Jeremy Rich, John Sampson,
Valerie Stafford-Fox, Karen Ziegler, Darell D Bigner, Henry Friedman
Treatment of adults with recurrent
malignant glioma using temozolomide plus CPT-11: a phase I study
38th
ASCO Annual Meeting. Orlando, FL. May 18-21, 2002.
2096
|
|
|
J. J. Vredenburgh, A. Desjardins, J. E. Herndon, J. Quinn, J. Rich, S.
Sathornsumetee, H. S. Friedman, D. Reardon, S. Gururangan, A. Friedman
Bevacizumab, a monoclonal antibody to vascular endothelial growth factor
(VEGF),
and irinotecan for treatment of malignant gliomas
Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings
(Post-Meeting Edition).
Vol 24, No 18S (June 20 Supplement), 2006: 1506
|
|
|
Non-Nervous
System Tumors
|
|
|
|
Mori
K, Kondo T, Kamiyama Y, Kano Y, Tominaga K
Preventive
effect of Kampo medicine (Hangeshashin-to) against irinotecan-induced diarrhea
in advanced non-small-cell lung cancer
Cancer Chemother Pharmacol 2003 Apr 9; [epub ahead of print]
|
|
|
Pediatric
Brain Tumors
|
|
|
|
|
Bomgaars LR, Bernstein M, Krailo M, Kadota R, Das S, Chen Z, Adamson PC, Blaney SM.
Phase II trial of irinotecan in
children with refractory solid tumors: a Children's Oncology Group Study.
J
Clin Oncol. 2007 Oct 10;25(29):4622-7.
Abstract
|
|
|
Topoisomerase
I inhibitors
|
|
|
|
Ewesuedo
RB, Ratain MJ
Topoisomerase
I Inhibitors
Oncologist 1997;2(6):359-364 (PDF Full Text)
|
|
